NO20063393L - Farmasoytiske preparater - Google Patents

Farmasoytiske preparater

Info

Publication number
NO20063393L
NO20063393L NO20063393A NO20063393A NO20063393L NO 20063393 L NO20063393 L NO 20063393L NO 20063393 A NO20063393 A NO 20063393A NO 20063393 A NO20063393 A NO 20063393A NO 20063393 L NO20063393 L NO 20063393L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
antagonists
disclosed
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
NO20063393A
Other languages
English (en)
Inventor
Mengwei Hu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20063393L publication Critical patent/NO20063393L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytiske preparater som omfatter NKl-antagonister beskrives.
NO20063393A 2003-12-22 2006-07-21 Farmasoytiske preparater NO20063393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53173503P 2003-12-22 2003-12-22
PCT/US2004/042893 WO2005063243A1 (en) 2003-12-22 2004-12-20 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20063393L true NO20063393L (no) 2006-07-21

Family

ID=34738689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063393A NO20063393L (no) 2003-12-22 2006-07-21 Farmasoytiske preparater

Country Status (16)

Country Link
US (1) US20050153999A1 (no)
EP (1) EP1706116A1 (no)
JP (1) JP2007515425A (no)
KR (1) KR20060113737A (no)
CN (1) CN1897942A (no)
AR (1) AR046769A1 (no)
AU (1) AU2004308935A1 (no)
BR (1) BRPI0417950A (no)
CA (1) CA2550432A1 (no)
MX (1) MXPA06007210A (no)
NO (1) NO20063393L (no)
PE (1) PE20051049A1 (no)
PL (1) PL380482A1 (no)
TW (1) TW200531686A (no)
WO (1) WO2005063243A1 (no)
ZA (1) ZA200605080B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648640C (en) * 2006-04-05 2016-02-16 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2007114922A2 (en) * 2006-04-05 2007-10-11 Schering Corporation Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
TWI363058B (en) * 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
UA99787C2 (en) * 2008-11-23 2012-09-25 Пфайзер Инк. Lactams as beta secretase inhibitors
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
AU2014271269B2 (en) * 2009-08-14 2016-11-03 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
NL2018041B1 (en) * 2016-12-22 2018-06-28 Land Life Company B V Process to prepare a biodegradable pulp product
EP3968979B1 (en) * 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
KR102940508B1 (ko) * 2019-06-28 2026-03-16 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 뉴로키닌-1 길항제
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
JP2024501994A (ja) * 2020-12-25 2024-01-17 上海盛迪医▲葯▼有限公司 Ｎｋ１拮抗剤プロドラッグ化合物と５－ｈｔ３受容体拮抗剤との併用使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1

Also Published As

Publication number Publication date
AR046769A1 (es) 2005-12-21
US20050153999A1 (en) 2005-07-14
JP2007515425A (ja) 2007-06-14
CN1897942A (zh) 2007-01-17
WO2005063243A1 (en) 2005-07-14
BRPI0417950A (pt) 2007-04-17
ZA200605080B (en) 2008-06-25
EP1706116A1 (en) 2006-10-04
PE20051049A1 (es) 2006-01-03
TW200531686A (en) 2005-10-01
AU2004308935A1 (en) 2005-07-14
KR20060113737A (ko) 2006-11-02
CA2550432A1 (en) 2005-07-14
PL380482A1 (pl) 2007-02-05
MXPA06007210A (es) 2006-08-18

Similar Documents

Publication Publication Date Title
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
ITTO20000779A0 (it) Composizioni farmaceutiche.
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
KR20050009999A (ko) 약제학적 제제
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
SE0302811D0 (sv) Novel compounds
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
SE0301653D0 (sv) Novel compounds
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
EE200300589A (et) Ravimkoostised
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
TW200531686A (en) Pharmaceutical compositions
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
BRPI0417205A (pt) composições farmacêuticas
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application